Research by Horiguchi et al. corroborated a significant downregulation of RUNX3 in pancreatic cancer, with median survival durations for patients exhibiting normal and reduced RUNX3 expression being 1006 and 643 days, respectively, thereby establishing the negative prognostic impact of RUNX3 downregulation [88]. Here, RUNX3 is linked to pancreatic neoplasm.